Last reviewed · How we verify
Favipiravir plus Nitazoxanide
At a glance
| Generic name | Favipiravir plus Nitazoxanide |
|---|---|
| Also known as | FPV-NTZ |
| Sponsor | Shin Poong Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Favipiravir plus Nitazoxanide CI brief — competitive landscape report
- Favipiravir plus Nitazoxanide updates RSS · CI watch RSS
- Shin Poong Pharmaceutical Co. Ltd. portfolio CI